Thomas Rosamond, MD
Cardiovascular Disease · Kansas City, KSNPI 1356454912
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Pfizer at 29.1% of the total. Reporting peaked in 2019 at $615 and has fallen 69.8% since, to $186 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in KS, where the typical reported total is $2,383.
Across 64 payments — averaging $28.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$534
- Lantheus Medical Imaging, Inc.$159
- Medtronic$146
- Abbott$128
- GE HealthCare$122
- E.r. Squibb & Sons, L.L.C.$109
- plus $637 from 15 others
Across 7 payments — averaging $8366.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$59K
What the payments were for
- Food & beverage$1,82699%
- Education$101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 21 | $534 |
| Lantheus Medical Imaging, Inc. | 4 | $159 |
| Medtronic | 2 | $146 |
| Abbott | 3 | $128 |
| GE HealthCare | 3 | $122 |
| E.r. Squibb & Sons, L.L.C. | 6 | $109 |
| Bracco Diagnostics Inc. | 1 | $107 |
| Boston Scientific | 3 | $102 |
| Astellas Pharma US Inc | 3 | $71 |
| AstraZeneca | 3 | $54 |
| Edwards Lifesciences | 1 | $43 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $41 |
| Heartflow, Inc. | 1 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Amgen | 2 | $34 |
| Novo Nordisk | 2 | $30 |
| Novartis | 1 | $18 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Siemens Medical Solutions USA, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$250
- Definity$110
- LUMASON$107
- COBALT DR MRI SURESCAN$106
How this compares
$1,835 in reported general payments places this provider in the 45th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $109,011 |
| Repatha SureclickEvolocumab | 89 | $73,025 |
| Praluent PenAlirocumab | 74 | $39,958 |
| XareltoRivaroxaban | 38 | $38,625 |
| Flecainide Acetate | 27 | $1,888 |
| Metoprolol Succinate | 87 | $1,500 |
| Atorvastatin Calcium | 126 | $1,276 |
| Potassium Chloride | 28 | $1,213 |
| Nebivolol Hcl | 73 | $996 |
| Ezetimibe | 60 | $938 |
| Rosuvastatin Calcium | 98 | $757 |
| Carvedilol | 95 | $700 |
| Diltiazem 24hr ErDiltiazem Hcl | 13 | $660 |
| Amlodipine Besylate | 100 | $650 |
| ClopidogrelClopidogrel Bisulfate | 63 | $623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $534 | $109,011120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Kansas City
- Timothy BeaverKansas City$22K
- Jayant NathKansas City$18K
- Donald McSweynKansas City$12K
- Jean-Alfred ThomasKansas City$11K
- Seyedhamed HosseinidehkordiKansas City$8K
- Mohammad AlarfajKansas City$7K
- Matthew KellingKansas City$6K
- Justin UgwuKansas City$5K
- Jonathan FreemanKansas City$4K
- Abdulrahman MoradKansas City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.